Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,284.20 | 51.60 | 0.56% |
| CAC 40 | 7,938.29 | 34.74 | -0.44% |
| DAX 40 | 24,293.34 | 16.37 | 0.07% |
| Dow JONES (US) | 44,813.85 | 124.46 | -0.28% |
| FTSE 100 | 9,309.20 | 21.06 | 0.23% |
| HKSE | 25,104.61 | 61.33 | -0.24% |
| NASDAQ | 21,094.08 | 78.78 | -0.37% |
| Nikkei 225 | 42,610.17 | 278.38 | -0.65% |
| NZX 50 Index | 13,194.07 | 122.77 | 0.94% |
| S&P 500 | 6,374.90 | 20.88 | -0.33% |
| S&P/ASX 200 | 9,019.10 | 45.40 | 0.51% |
| SSE Composite Index | 3,771.10 | 4.89 | 0.13% |